Devising Multi-Target Systems Biology Procedure to Inhibit Transition from In-Situ Ductal Carcinoma to Invasive Ductal Carcinoma

سال انتشار: 1397
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 379

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

CIGS15_235

تاریخ نمایه سازی: 13 بهمن 1398

چکیده مقاله:

In-situ form of cancer tumor stays at its initial tissue location without spreading around to cause further trouble to the patient but in its invasive form extends to other tissues and become uncontrollable. Breast cancer (BC), the most relevant type of cancer among women, is divided into In-situ Ductal Carcinoma (IDC) and Ductal Invasive Carcinoma (DIC). Transcription Factors (TFs) involved in transition from IDC to DIC play important role so that their targeting inhibits metastasis.In this study, we used microarray dataset in GEO (GSE21422) to reach up regulated form of differentially expressed genes (DEGs). The expression profile of DIC and IDC groups were compared together by log fold change and adjusted p-Value parameters. The DEGs’ list obtained was given to chEA database to find TFs and then to TargetScan microRNA database to predict miRNAs regulating them. The most affected pathway has been determined by Reactome and cancer cell line mapping has been performed by Cancer Cell Line Encyclopedia.Our results suggested BACH1, ESR1, NR3C1, P53 and WT1 as involved TFs. Then miR-154 appeared to be the most effective miRNA regulating our DEGs. We have mapped KPNSI9S (Glioblastoma), HS571T (Ovarian) and HS274T (Breast) as top 3 cell lines affected by determined DEGs and Signaling by FGFR recognized as the most affected pathway. In conclusion, we identify TFs that can be targeted to prevent metastasis. Also by cell line mapping we propose that by targeting these TFs, other kinds of cancer can also be targeted simultaneously.

کلیدواژه ها:

نویسندگان

Farzaneh Afzali

Dept. of Stem Cells and Regenerative Medicine, Faculty of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran

Mossa Gardaneh

Dept. of Stem Cells and Regenerative Medicine, Faculty of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran

Zahra Nayeri

Molecular Medicine Department, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology , Tehran, Iran